Trikafta access in Saudi Arabia: the SFDA Personal Importation Program

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Trikafta is the Vertex Pharmaceuticals triple-combination CFTR modulator approved by the US FDA in October 2019 for cystic fibrosis patients aged 2 years and older who carry at least one F508del mutation in the CFTR gene. In the Kingdom of Saudi Arabia the product (also marketed in some markets as Kaftrio) has been available through hospital channels and named-patient routes, but local retail stocking is sporadic, and chronic CFTR-modulator therapy cannot tolerate weeks-long gaps. Saudi families on established Trikafta therapy frequently turn to a cross-border named-patient pathway when stocking lapses, when payer pathways prefer older modulators, or when the family chooses to stay on Trikafta rather than accept a substitution. The Saudi Food and Drug Authority (SFDA) operates the Personal Importation Program (PIP), the lawful route for a patient-specific import.

Reserved for you.

Why Saudi families reach for Trikafta through NPP

Saudi Arabia operates one of the most mature pharmaceutical regulatory frameworks in the Gulf Cooperation Council, and SFDA has run a developed named-patient framework for over a decade. Three structural access gaps still apply. A drug can be registered with SFDA but not stocked at the treating hospital's pharmacy on the day a patient needs it. A drug can be registered for one indication and prescribed for a different FDA-approved indication that is not on the local label. A drug can be FDA-approved and never registered in the Kingdom at all. For Trikafta the dominant pattern in this market is the first: known and used through hospital channels at several tertiary centers, but routine retail stocking is uneven and continuity gaps are common, particularly for pediatric strengths and granule packets.

The named-patient case for Trikafta also rests on the drug itself. Roughly 90 percent of people with cystic fibrosis carry at least one F508del allele, which is the eligibility gate for Trikafta. The FDA label was extended to ages 6 and older in June 2021, then to ages 2 and older in April 2023, which broadened the Saudi pediatric population eligible for the drug. Vertex launched the once-daily successor Alyftrek (vanzacaftor, tezacaftor, deutivacaftor) in the United States in December 2024, and some payer systems are pushing new starts toward that successor. Many established Saudi Trikafta patients, supported by longer real-world experience and existing prior-authorization templates, prefer to remain on Trikafta. The cross-border named-patient route gives them that continuity.

The SFDA Personal Importation Program for Trikafta

The SFDA Personal Importation Program allows a Saudi-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognized reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable for the patient. The framework explicitly contemplates oncology, rare disease, immunology, neurology, hematology, and pediatric specialty therapies. Applications are filed through the dispensing institution's import pharmacy and reviewed by SFDA's Drug Sector through the agency's Ghad digital platform.

For Trikafta the clinical-justification angle is genotype-specific. A complete application typically includes:

• A clinical justification letter from the treating CF physician naming the patient's CFTR genotype (at least one F508del mutation, or another responsive variant on the current FDA label), prior CFTR-modulator history if any, clinical status, and why this specific drug is required, with ICD-10 coding
• The treating physician's Saudi Commission for Health Specialties (SCFHS) license verification in the relevant specialty (pediatric pulmonology, adult pulmonology with CF subspecialty, or CF-center medical direction)
• An anonymised patient identifier in the format SFDA requires for the named-patient case file
• Product details: Trikafta, elexacaftor 100 mg / tezacaftor 50 mg / ivacaftor 75 mg morning tablet plus ivacaftor 150 mg evening tablet (or the appropriate pediatric strength or granule packet), manufacturer Vertex Pharmaceuticals, country of origin, pack size, requested quantity, lot, and expiry
• The destination dispensing facility license number, confirming the receiving pharmacy is SFDA-licensed to handle imported pharmaceuticals
• A chain-of-custody plan from the US specialty-pharmacy point of release through international transit to the receiving Saudi pharmacy, including the freight forwarder, customs broker, and importer of record

Approval timelines for routine cases (recognized reference-authority drug, well-documented F508del genotype, established institution) typically run 10 to 21 business days. Complex cases (first-time import of the molecule through a smaller importer, non-F508del responsive variant requiring extra label review, ultra-rare patient population) can extend to 6 to 10 weeks. Trikafta is room-temperature stable, so timelines are not pinched by cold-chain logistics, but the pediatric granule packets carry their own dispensing-pharmacy verification steps. The clinical letter and the CFTR genetic-testing report are the cornerstones of the package regardless of who files.

Where Trikafta gets dispensed in Saudi Arabia

Trikafta is an oral therapy. There is no infusion-centre requirement, and the dispensing footprint is broader than for cold-chain biologics. Tertiary hospitals with established import-pharmacy infrastructure handle Trikafta as routine workflow. The KSA institutions that file named-patient imports as established practice include King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Jeddah, and Madinah; King Abdulaziz Medical City (KAMC) and the Ministry of National Guard Health Affairs network (MNGHA) in Riyadh and Jeddah; King Saud University Medical City (KSUMC) and KSAU-HS affiliated centers; Dr. Sulaiman Al Habib Medical Group (HMG) across Riyadh, Jeddah, and the Eastern Province; Saudi German Health; Dr. Soliman Fakeeh Hospital in Jeddah; and Dallah Hospital in Riyadh.

For pediatric CF cases the natural homes are the pediatric pulmonology services at KFSH&RC (with the largest CF-pediatric experience in the Kingdom), the pediatric services at KAMC and MNGHA, and the pediatric programs at HMG and Saudi German. Families in the Eastern Province, Madinah, Tabuk, Asir, or other regions without a local CF center typically route to a Riyadh or Jeddah facility where their physician holds privileges, or to a Riyadh- or Jeddah-based SFDA-licensed specialty importer that files the PIP, handles chain-of-custody documentation, and transfers the drug under the institutional license to the prescribing hospital's outpatient pharmacy.

Real cost picture for Trikafta in Saudi Arabia

US wholesale acquisition cost for Trikafta is approximately USD 322,000 per patient per year, which works out to roughly USD 26,800 per month for adult-strength dosing. The Saudi riyal is pegged to the US dollar at approximately 3.75 SAR to 1 USD, so monthly drug acquisition translates to roughly SAR 100,500 at US WAC. The named-patient acquisition cost sits between US WAC and confidential negotiated payer prices in Europe and is finalised only on firm-quote issuance after document review.

International logistics for Trikafta runs at the lower end of the Reserve Meds lane range, typically USD 400 to USD 800 (approximately SAR 1,500 to SAR 3,000), because the product is ambient-controlled rather than cold-chain. SFDA permit handling fees and Saudi customs charges are nominal relative to the drug itself. Reserve Meds' coordination fee is itemised separately on every firm quote. On the insurance side, Bupa Arabia, Tawuniya (The Company for Cooperative Insurance), and MedGulf Arabia each assess named-patient imports case by case. Some plans reimburse fully when the molecule is on the insurer's formulary even if not stocked locally; others reimburse a percentage; many require pre-authorisation with the clinical justification letter attached. The Council of Cooperative Health Insurance (CCHI) is the regulator that governs plan structure. Reserve Meds supplies the documentation the insurer needs to assess; the claim itself remains with you or the hospital.

Typical timeline for Trikafta in Saudi Arabia

For an established Trikafta patient with a clean F508del genotype letter, a current weight-band confirmation, and a CF-center referral, the typical end-to-end cycle is 4 to 8 weeks. The SFDA PIP step generally runs 10 to 21 business days for routine cases. US-side sourcing and release through the Vertex specialty-pharmacy network adds approximately 1 to 2 weeks. International ambient-controlled transit and Saudi customs clearance under the import permit are typically 3 to 7 days. For first-time imports through a smaller importer or for non-F508del responsive-variant cases, the front-end permit step can extend to 6 to 10 weeks. Timelines are presented as typical ranges, not promises; specific dates are confirmed at firm-quote issuance.

What your physician needs to provide

The clinical justification letter for Trikafta is the centrepiece of the SFDA package. For this product the letter typically includes:

• The patient's confirmed cystic fibrosis diagnosis with ICD-10 coding and CFTR genotype (at least one F508del allele documented on the genetic-testing report, or another responsive variant on the current FDA label)
• The patient's current age and weight, with the weight band that determines the appropriate Trikafta strength (adult strength for patients aged 12 and older or pediatric patients 25 kg and above; lower-strength tablet for patients 6 to 11 under 25 kg; granule packets for patients ages 2 to 5 in two weight bands at 10 kg and 14 kg thresholds)
• Prior CF treatment history and any prior CFTR-modulator exposure (Kalydeco, Orkambi, Symdeko, or Trikafta itself)
• Justification for why a locally registered alternative is not suitable (often this is continuity of an established response, or absence of a clinically equivalent on-label alternative)
• The dosing plan: morning tablet plus evening tablet 12 hours apart, both with fat-containing food required for adequate ivacaftor absorption
• The monitoring plan: baseline and periodic liver function tests (ALT, AST, bilirubin) every three months for the first year then annually; baseline and follow-up ophthalmologic examination in pediatric patients for cataracts; medication reconciliation for CYP3A interactions (rifampin and St John's wort contraindicated, strong inhibitors requiring dose reduction to twice-weekly)
• The pharmacovigilance commitment to report any adverse event through the SFDA National Pharmacovigilance Center for the full course of therapy

Public-sector physicians at KFSH&RC, KAMC, MNGHA, KSUMC, and Ministry of Health hospitals hold full signing authority on PIP applications under their SCFHS license. Private-sector physicians at HMG, Saudi German, Fakeeh, Dallah, and similar institutions also sign PIP applications under their institutional license.

Common questions about Trikafta in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover Trikafta? Each insurer assesses named-patient imports case by case. Some plans reimburse fully when the molecule is on their formulary even if not currently stocked, others reimburse a percentage, many require pre-authorisation with the clinical justification letter attached. Reserve Meds does not promise coverage. We supply the documentation set that lets your insurer assess the case; the claim itself remains with you or your hospital.

Is my Ministry of Health-employed or KFSH&RC pediatric pulmonologist's letter sufficient if SFDA flags the case? Yes. Any SCFHS-licensed physician in good standing at a Ministry of Health hospital, KFSH&RC, KAMC, MNGHA, or other public-sector institution has full signing authority on PIP applications. Private-sector physicians at HMG, Saudi German, Fakeeh, and Dallah also sign under their institutional license.

What if my child is under 2 years old? Trikafta is approved for patients aged 2 years and older. Reserve Meds will not coordinate intake for a patient outside the FDA-approved age range. We will route the family to local CF-center care planning until the patient reaches eligibility.

What about Alyftrek? Alyftrek (vanzacaftor, tezacaftor, deutivacaftor) is Vertex's once-daily successor approved by the FDA in December 2024. Trikafta has longer real-world experience, broader international registration, established payer pathways, and in several markets a lower acquisition cost. Switching is a clinician-driven decision and not one Reserve Meds makes.

What is the safety profile? Most common adverse events on the pivotal trials (VX17-445-102 and VX17-445-103) were headache, upper respiratory infection, abdominal pain, rash, and elevated transaminases. Drug-induced liver injury, cataracts in pediatric patients, and hypersensitivity reactions are labeled warnings. Baseline and periodic liver function testing and pediatric ophthalmologic examination are part of the monitoring plan.

Can the medicine be delivered to our home? The dispensing facility must be a Saudi-licensed pharmacy. For Trikafta the medicine moves into a hospital outpatient pharmacy or a specialised SFDA-licensed import pharmacy, and the family collects it from there. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.

Where Reserve Meds fits in Trikafta cases

Reserve Meds is a US-based concierge coordinator. We do not replace your CF physician, do not replace SFDA, and do not replace the dispensing pharmacy. For Trikafta specifically we orchestrate the US-side sourcing through the Vertex specialty-pharmacy network, the regulatory documentation kit your physician needs (genotype letter template, dosing reference by weight band, monitoring plan summary, SFDA pharmacovigilance reference), international ambient-controlled logistics under chain-of-custody, and a single named coordinator who carries the family from intake through delivery and reorders. F508del genotype documentation, CF-center referral letter, and current weight-band confirmation are mandatory intake artefacts. We do not coordinate off-label use, and we will decline intake for patients without at least one F508del allele or another labeled CFTR-responsive variant.

Next step

If your CF physician has decided Trikafta is the right next step and local stocking is the bottleneck, the named-patient pathway through SFDA is the route. Join the waitlist below and we will confirm eligibility within 24 to 48 hours and route the documentation kit to your physician.

Join the Trikafta waitlist

Reserved for you.